Table 1.
Patient characteristics according to TMTV and circulating parameters
| Patients with TMTV, n = 133 | TMTV > 510, n = 50/133 | Patients with cfDNA analyses, n = 61 | Patients with cfDNA > 2550, n = 37/61 | Patients with evaluable* CTCs, n = 68 | Patients with CTCs > 0.0018, n = 42/68 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n (missing) | % | n (missing) | % | n (missing) | % | n (missing) | % | n (missing) | % | n (missing) | % | |
| Median age (range), y | 60 (28-75) | 61 (31-77) | 62 (34-77) | 64 (41-77) | 59 (33-75) | 58 (33-75) | ||||||
| Age >60 y | 64 | 48 | 26 | 52 | 33 | 54 | 23 | 62 | 28 | 41 | 17 | 40 |
| Female sex | 68 | 51 | 22 | 44 | 32 | 52 | 16 | 43 | 33 | 49 | 17 | 40 |
| Ann Arbor stage III-IV | 126 | 95 | 50 | 100 | 58 | 95 | 36 | 97 | 67 | 99 | 42 | 100 |
| No. of involved areas >4 | 83 (3) | 64 | 42 (2) | 87† | 46 | 75 | 32 | 86† | 44 | 65 | 32 | 76 |
| Bone marrow biopsy (+) | 78 (5) | 61 | 40 (1) | 81† | 39 (1) | 65 | 26 (1) | 72 | 41 (3) | 63 | 36 (1) | 88† |
| LodLIN (cm) >6 | 47 (5) | 37 | 20 | 40 | 19 | 31 | 13 | 35 | 20 (1) | 30 | 13 (1) | 32 |
| LDH >Nl | 20 | 15 | 09 | 18 | 13 | 21 | 10 | 27 | 11 | 16 | 8 | 19 |
| β2-microglobulin >Nl | 68 (13) | 57 | 38 (4) | 83† | 35 | 57 | 27 | 73 | 33 (12) | 59 | 26 (6) | 72 |
| FLIPI score 3-4 | 61 | 46 | 31 | 62 | 34 | 56 | 25 | 68* | 31 | 46 | 20 | 48 |
| FLIPI2 score 3-4 | 55 (6) | 43 | 30 (2) | 62* | 28 (1) | 47 | 23 (1) | 64* | 28 (5) | 44 | 21 (2) | 52 |
| Median SUVmax (range) | 8.8 (2.4-27.6) | 8.36 (3.41-27.6) | 9.63 (2.4-21.8) | 10.6 (2.38-18.3) | 9.0 (4.99-27.6) | 8.31 (4.99-27.6) | ||||||
| Median TMTV, cm3 (range) | 354 (14-7796) | 855 (520-7796) | 392 (17-7795) | 724 (17-7795) | 413 (32-3432) | 658 (32-3432) | ||||||
| First-line treatment | ||||||||||||
| R chemo‡ | 48 | 36 | 19 | 38 | 17 | 28 | 9 | 24 | 23 | 34 | 13 | 31 |
| R chemo‡ + M | 60 | 45 | 19 | 38 | 29 | 47 | 16 | 43 | 27 | 40 | 18 | 43 |
| Chemo-free§ | 4 | 3 | — | — | 2 | 3 | 1 | 3 | 1 | 1 | — | — |
| Chemo-free§ + M | 21 | 16 | 12 | 24 | 13 | 21 | 11 | 30 | 17 | 25 | 11 | 26 |
Chi-squared comparison of parameters between patients with high levels and total analyzed population. Values are “n (missing)” and “%” of patients except as noted.
LDH, lactate dehydrogenase; M, Revlimid maintenance; R, Revlimid.
P < .05.
P < .01.
R chemo: PRIMA-like R-CHOP R (6 cycles of R-CHOP [rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone] plus 2 cycles of rituximab): n = 84. R2-CHOP (addition of lenalidomide [Revlimid; Celgene] to the R-CHOP regimen): n = 15. Other R-chemo schedule: n = 9.
Chemo-free: R2 (oral lenalidomide 20 mg for 21 days in a 28-day cycle, with rituximab 375 mg/m2 given intravenously on day 1 of each cycle for at least 6 cycles): n = 23; Revlimid alone (n = 2).